These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 19038756)

  • 1. Lung cancer: moving forward with tailored strategies.
    Barlesi F
    Lancet Oncol; 2008 Dec; 9(12):1116-7. PubMed ID: 19038756
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung cancer may be different for men and women, but researchers ponder what to do?
    Hede K
    J Natl Cancer Inst; 2007 Dec; 99(24):1830-2. PubMed ID: 18073369
    [No Abstract]   [Full Text] [Related]  

  • 3. [Management of side effects with platinum doublet chemotherapy used for treatment of non-small cell lung cancer].
    Kudo K; Nakagawa K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():542-7. PubMed ID: 25831819
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy for advanced lung cancer.
    Blackhall F; Thatcher N
    Eur J Cancer; 2004 Nov; 40(16):2345-8. PubMed ID: 15519503
    [No Abstract]   [Full Text] [Related]  

  • 5. Platinum-based chemotherapy in non-small cell lung cancer: the experience of the European Organization for the Research and Treatment of Cancer.
    van Zandwijk N; Dalesio O
    Semin Oncol; 1994 Jun; 21(3 Suppl 6):66-71. PubMed ID: 8052876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial carboxyhemoglobin concentrations as a prognostic predictor in elderly patients with advanced non-small-cell lung cancer.
    Yasuda H; Nakayama K; Ebihara S; Asada M; Sasaki T; Suzuki T; Inoue D; Yoshida M; Yamanda S; Yamaya M
    J Am Geriatr Soc; 2006 Apr; 54(4):712-3. PubMed ID: 16686889
    [No Abstract]   [Full Text] [Related]  

  • 7. Platinum-based second-line treatment in non-small-cell lung cancer: an old new kid on the block?
    de Lima Araújo LH; Ferreira CG
    J Clin Oncol; 2010 Jan; 28(2):e24-5; author reply e26. PubMed ID: 19933903
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
    Sangha R; Lara PN; Mack P; Gandara DR
    Clin Lung Cancer; 2008; 9 Suppl 3():S90-1. PubMed ID: 19419929
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.
    Prescrire Int; 2009 Feb; 18(99):11. PubMed ID: 19385126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?
    Gridelli C; Rossi A; Maione P; Ambrosio R; Barbato V; Bareschino MA; Schettino C; Palazzolo G; Sacco PC
    Clin Lung Cancer; 2010 Nov; 11(6):374-82. PubMed ID: 21062728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of tumor markers in monitoring of cytotoxic treatment of non-small cell lung cancer].
    Załeska M
    Pneumonol Alergol Pol; 2003; 71(7-8):359-64. PubMed ID: 15052970
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
    Zych J; Sakowicz A; Radzikowska E; Załeska J; Rowińska-Zakrzewska E
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():173-8. PubMed ID: 9337535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics of Ca(2+)-induced response of erythrocytes in patients with lung cancer during antineoplastic chemotherapy].
    Petrova IV; Stepovaia EA; Sokolova IB; Gol'dberg VE; Chasovskikh NIu; Koreshkova KG; Bazhenova NG; Kolosova MV; Baskakov MB; Novitskiĭ VV; Medvedev MA
    Biull Eksp Biol Med; 1997 Aug; 124(8):195-8. PubMed ID: 9410209
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
    Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
    Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).
    Dehing-Oberije C; Aerts H; Yu S; De Ruysscher D; Menheere P; Hilvo M; van der Weide H; Rao B; Lambin P
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):360-8. PubMed ID: 20888135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
    J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
    Felip E; Rojo F; Reck M; Heller A; Klughammer B; Sala G; Cedres S; Peralta S; Maacke H; Foernzler D; Parera M; Möcks J; Saura C; Gatzemeier U; Baselga J
    Clin Cancer Res; 2008 Jun; 14(12):3867-74. PubMed ID: 18559607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.